Original Research

Serum Visfatin Levels in Pregnant Women with Gestational Diabetes Mellitus

DOI https://doi.org/10.70302/jpsim.v2i3.2149
Received: 27 May 2021 Accepted: 26 Jul 2021 Published Online: 20 Sep 2021

Abstract

Objective

The clinical data linking circulating visfatin to the parameters of glucose metabolism and insulin resistance during gestational diabetes mellitus (GDM) pregnancy is widely contentious. Aim of this study is to explore the changes in maternal serum visfatin levels in normal and pregnancy complicated with gestational diabetes mellitus (GDM).

Methods

This study was carried out in Lahore General Hospital /PGMI. Forty two pregnant females in the age range 25-35 years, at 32-36 weeks of gestation was included in this study and divided into two groups. Group1 includes 21 normal healthy pregnant females as control and Group II includes diagnosed cases of GDM. Fasting blood samples were drawn during 32-36 weeks of gestation for serum visfatin, fasting insulin and fasting blood sugar.
Serum visfatin levels were determined by visfatin/Nampt/PBEF human ELISA kit manufactured by Glory science company, USA. Serum Insulin was determined by using Insulin ELISA Kit manufactured by Calbiotech company, USA. Serum glucose was determined by chemistry analyzer Micro lab 300. Homeostasis Model Assessment (HOMA)-IR was used as an insulin resistance index which was obtained by the product of fasting blood glucose and fasting levels of insulin and dividing it by 22.5.
The data was entered and analyzed by using SPSS-23. Mean + SD was calculated for quantitative variables. Independent sample and paired t-test were applied and statistical significance was considered with a p<0.05.

Results

Levels of serum Vistafin were compared amongst group I and group II during third trimester revealed a statistically significant difference (p=0.00).

Conclusion

Visfatin has been suggested to have a role in pathogenesis of GDM as it appears to be considered in regulation of glucose metabolism and insulin resistance.

Keywords
Visfatin Level Gestational Diabetes Mellitus Homeostasis Model Assessment.

How to Cite This Article

Yasmin S, Chaudhry SR, Saeed M, Iqbal K, Meer5 I. Serum Visfatin Levels in Pregnant Women with Gestational Diabetes Mellitus. J Pak Soc Intern Med. 2021;2(3):215–217. doi:10.70302/jpsim.v2i3.2149

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. American Diabetes Association Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41(Suppl 1):13-27.
  2. International Diabetes Federation . IDF Diabetes Atlas. 8th ed. IDF; Brussels, Belgium: 2017.
  3. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11): 3342.
  4. Zhao Y, Liu XZ, Tian WW, Guan YF, Wang P, Miao CY. Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury. CNS Neurosci Therapeut. 2014;20(6):539-47.
  5. Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22. https://doi.org/10.3389/fcvm.2020.00022. doi:10.3389/fcvm.2020.00022
  6. Taşdemir E, Şermet A. The relationship between plasma adipsin, adiponectin, vaspin, visfatin, and leptin levels with glucose metabolism and diabetes parameters. Diabetes. 2019;15:21. DOI: 10.14744/hnhj.2019.62534 doi:10.14744/hnhj.2019.62534
  7. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133-223.
  8. Hussein MK, Hamza AA, Ahmed AA. Relation Between Visfatin, Body Mass Index with Insulin Resistance in Type 2 Diabetic Iraqi Patients. University of Thi-Qar Journal Of Medicine. 2020;20(2):185-90.
  9. Nicholson T, Church C, Baker DJ, Jones SW. The role of adipokines in skeletal muscle inflammation and insulin sensitivity. J Inflam. 2018;15(1):1-1.
  10. Liang Z, Wu Y, Xu J, Fang Q, Chen D. Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus. J Diab Invest. 2016;7(2):247-52.
  11. Radzicka S, Pietryga M, Iciek R, Brązert J. The role of visfatin in pathogenesis of gestational diabetes (GDM). Ginekologia Polska. 2018;89(9):518-21.
  12. Jiang YK, Deng HY, Qiao ZY, Gong FX. Visfatin level and gestational diabetes mellitus: a systematic review and meta-analysis. Arch Physiol Biochem. 2021; doi: 10.1080/13813455.2021.1874997. doi:10.1080/13813455.2021.1874997
  13. Liang Z, Wu Y, Xu J, Fang Q, Chen D. Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus. Journal of diabetes investigation. 2016 Mar;7(2):247-52.
  14. Tanaka K, Yamada K, Matsushima M, Izawa T, Furukawa S, Kobayashi Y, Iwashita M. Increased maternal insulin resistance promotes placental growth and decreases placental efficiency in pregnancies with obesity and gestational diabetes mellitus. J Obstetrics Gynaecol Res. 2018;44(1):74-80.
  15. Radzicka S, Pietryga M, Iciek R, Brązert J. The role of visfatin in pathogenesis of gestational diabetes (GDM). Ginekologia Polska. 2018;89(9):518-21.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2021 Journal of Pakistan Society of Internal Medicine.